We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Combination of [ 177 Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model.
- Authors
Simón, Marina; Jørgensen, Jesper Tranekjær; Khare, Harshvardhan A.; Christensen, Camilla; Nielsen, Carsten Haagen; Kjaer, Andreas
- Abstract
Peptide receptor radionuclide therapy (PRRT) relies on α- and β-emitting radionuclides bound to a peptide that commonly targets somatostatin receptors (SSTRs) for the localized killing of tumors through ionizing radiation. A Lutetium-177 (177Lu)-based probe linked to the somatostatin analog octreotate ([177Lu]Lu-DOTA-TATE) is approved for the treatment of certain SSTR-expressing tumors and has been shown to improve survival. However, a limiting factor of PRRT is the potential toxicity derived from the high doses needed to kill the tumor. This could be circumvented by combining PRRT with other treatments for an enhanced anti-tumor effect. Photothermal therapy (PTT) relies on nanoparticle-induced hyperthermia for cancer treatment and could be a useful add-on to PRRT. Here, we investigate a strategy combining [177Lu]Lu-DOTA-TATE PRRT and nanoshell (NS)-based PTT for the treatment of SSTR-expressing small-cell lung tumors in mice. Our results showed that the combination treatment improved survival compared to PRRT alone, but only when PTT was performed one day after [177Lu]Lu-DOTA-TATE injection (one of the timepoints examined), showcasing the effect of treatment timing in relation to outcome. Furthermore, the combination treatment was well-tolerated in the mice. This indicates that strategies involving NS-based PTT as an add-on to PRRT could be promising and should be investigated further.
- Subjects
CANCER treatment; SOMATOSTATIN receptors; LABORATORY mice; PEPTIDE receptors; ANIMAL disease models
- Publication
Pharmaceutics, 2022, Vol 14, Issue 6, p1284
- ISSN
1999-4923
- Publication type
Article
- DOI
10.3390/pharmaceutics14061284